Skip to Main Content
Contribute Try STAT+ Today

As U.S. regulators approve more medicines under a so-called accelerated approval pathway, Medicare and Medicaid continue to spend more on treatments, even though the clinical benefits remain unproven, according to two new analyses.

Accelerated approval refers to early endorsements of medicines that treat serious conditions and fill an unmet medical need based on a surrogate marker that is “reasonably likely” to predict clinical benefits. From 1992 through 2020, the U.S. Food and Drug Administration issued more than 250 accelerated approvals, mostly cancer treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment